Asceneuron, a Swiss biotech company, secured $100 million in a Series C funding round led by Novo Holdings to advance its OGA inhibitors, particularly ASN51, aimed at treating neurodegenerative diseases like Alzheimer's by preventing tau protein aggregation. The drug is expected to enter a phase 2 trial later this year. Novo Holdings' investment reflects growing interest in breakthrough treatments for Alzheimer's, with Asceneuron's unique oral formulation potentially offering advantages over existing treatments. The financing involved a syndicate of investors, including EQT Life Sciences, OrbiMed, and others, emphasizing the potential of Asceneuron's pipeline and its leadership in tauopathies.